Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Shares Outstanding (Weighted Average) (2020 - 2025)

Historic Shares Outstanding (Weighted Average) for Enanta Pharmaceuticals (ENTA) over the last 8 years, with Q4 2025 value amounting to $28.7 million.

  • Enanta Pharmaceuticals' Shares Outstanding (Weighted Average) rose 3536.11% to $28.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $28.7 million, marking a year-over-year increase of 3536.11%. This contributed to the annual value of $21336.0 for FY2025, which is 84.61% up from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Shares Outstanding (Weighted Average) of $28.7 million as of Q4 2025, which was up 3536.11% from $21336.0 recorded in Q3 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Shares Outstanding (Weighted Average) registered a high of $28.7 million during Q4 2025, and its lowest value of $20171.0 during Q3 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $20.9 million (2022), whereas its average is $15.6 million.
  • Per our database at Business Quant, Enanta Pharmaceuticals' Shares Outstanding (Weighted Average) skyrocketed by 59.85% in 2024 and then surged by 3536.11% in 2025.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $20.4 million in 2021, then grew by 2.1% to $20.8 million in 2022, then rose by 1.31% to $21.1 million in 2023, then increased by 0.71% to $21.2 million in 2024, then surged by 35.36% to $28.7 million in 2025.
  • Its last three reported values are $28.7 million in Q4 2025, $21336.0 for Q3 2025, and $21.4 million during Q2 2025.